

| Measure  | Time<br>(in Months<br>to<br>Baseline <sup>1</sup> ) | Verum group | Placebo group | p-value <sup>2</sup> |
|--|---|-------------|---------------|----------------------|
| <b>Cognitive data</b>                          |   |             |               |                      |
| Included in analysis, n/n <sub>group</sub> (%) |   | 9/10 (90%)  | 9/10 (90%)    |                      |
| Change in ADAS-Cog <sup>b</sup> , mean ± SD    | 6   | 0 ± 3.8     | - 0.9 ± 5.7   | .65                  |
| min/med/max                                    |   | -8/1/5      | -9/0/9        |                      |
| Change in ADAS-Cog <sup>b</sup> , mean ± SD    | 12  | 2.1 ± 3.8   | 0.4 ± 5.6     | .82                  |
| min/med/max                                    |   | -4/2/8      | -10/2/7       |                      |
| Included in analysis, n/n <sub>group</sub> (%) |   | 8/10 (90%)  | 9/10 (80%)    |                      |
| Change in ADAS-Cog <sup>b</sup> , mean ± SD    | 18  | 5 ± 6.14    | 5.3 ± 5.4     | .70                  |
| min/med/max                                    |   | -2/5/16     | -5/7/11       |                      |

<sup>1</sup> Baseline = 0 Months, Endpoint = 18 Month; <sup>2</sup> Nonparametric Wilcoxon-Mann-Whitney-Test; ADAS-Cog = Alzheimer's Disease Assessment Scale-cognitive subscale; n = number of participants. Because of missings in the items of the test at different times, we had to exclude individual probands from the analysis.

<sup>b</sup>: Increase means a decrease of test performance

**Table 1: Primary endpoint: change of ADAS-Cog at different times.**